Physician profile
Chelsie L Monroe
NPI 1104235761
$998,314.20
in general payments reported to CMS, 2019-2025
32 companies · $417K in 2025
The $417K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,416 · 2022: $85K · 2023: $241K · 2024: $254K · 2025: $417K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $540K · Consulting Fee: $177K · Travel and Lodging: $102K · Honoraria: $60K · Food and Beverage: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $975 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $539,689.05 |
| Consulting Fee | $176,844.24 |
| Travel and Lodging | $101,577.39 |
| Honoraria | $60,150.50 |
| Food and Beverage | $32,935.41 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $975.00 |
| Education | $212.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $407,872.29 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $192,423.66 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $137,909.38 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $101,702.85 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $61,147.48 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41,198.45 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27,341.56 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $24,805.78 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $874.61 | 2022-2025 | Abilify Asimtufii, Rexulti, Rejoyn |
| Jazz Pharmaceuticals INC. | $757.48 | 2022-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $290.38 | 2024-2025 | Lumryz |
| Indivior INC. | $270.69 | 2022-2025 | Sublocade, Perseris |
| Janssen Scientific Affairs, LLC | $239.37 | 2024-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $230.25 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $196.77 | 2021-2025 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $162.95 | 2023 | Quviviq |
| Tris Pharma INC | $141.15 | 2025 | Onyda Xr, Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $120.15 | 2022 | |
| Sage Therapeutics, LLC | $95.16 | 2024 | |
| Uswm, LLC | $81.92 | 2023 | Lucemyra, Zimhi |
| Tempus Ai, INC | $80.71 | 2024 | |
| Supernus Pharmaceuticals, INC. | $51.29 | 2024 | Qelbree |
| Braeburn INC. | $46.06 | 2024 | Brixadi |
| Biogen, INC. | $41.51 | 2024 | |
| Bioxcel Therapeutics, INC. | $41.33 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.47 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $38.21 | 2021-2025 | Hetlioz, Fanapt |
| Eisai INC. | $30.35 | 2021 | |
| Impel Pharmaceuticals INC. | $27.83 | 2023 | Trudhesa |
| Brainsway USA INC | $25.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.08 | 2021 | |
| Corium, LLC | $14.59 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsie Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.